Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Mayo Clinic, Rochester, MN, United States

Survival: 14.5 months
Toxicity Grade: 3
Treatments: Chemotherapy
Country: United States
City/State/Province: Rochester, MN
Hospital: Mayo Clinic
Journal: Link
Date: 6/2005

Patients: This Phase II study involved 27 patients with metastatic malignant melanoma. Eighteen patients were men, and nine were women. The median age was 56. Metastatic sites included lymph nodes, liver, and lung.

Treatment: The treatment consisted of one chemotherapeutic agent: Bortezomib.

Toxicity: Grade 3 toxicities included sensory neuropathy, thrombocytopenia, constipation, fatigue, ileus, abdominal pain, and infection without neutropenia.

Results: The median overall survival was 14.5 months.
The authors however concluded, brotezomib "was not found to be effective in the treatment of patients with metastatic melanoma".

Correspondence: Svetomir N. Markovic, M.D.

E-mail to a Friend Email Physician More Information